The Medicines Co. (MDCO)

55.37
NASDAQ : Health Technology
Prev Close 55.01
Day Low/High 54.17 / 56.19
52 Wk Low/High 16.69 / 58.48
Avg Volume 2.19M
Exchange NASDAQ
Shares Outstanding 79.72M
Market Cap 4.39B
EPS -4.00
P/E Ratio N/A
Div & Yield N.A. (N.A)
Insider Trading Alert - MDCO, DXCM And WMGI Traded By Insiders

Insider Trading Alert - MDCO, DXCM And WMGI Traded By Insiders

Stocks with insider trader activity include MDCO, DXCM and WMGI

The Medicines Company To Present At Cowen And Company 36th Annual Health Care Conference

The Medicines Company To Present At Cowen And Company 36th Annual Health Care Conference

The Medicines Company (NASDAQ:MDCO) is scheduled to present at the Cowen and Company 36th Annual Health Care Conference in Boston, MA on Wednesday, March 9, 2016, at 8:40 AM EST.

The Medicines Company To Participate In 2016 RBC Capital Markets Global Healthcare Conference

The Medicines Company To Participate In 2016 RBC Capital Markets Global Healthcare Conference

The Medicines Company (NASDAQ:MDCO) is scheduled to participate at the 2016 RBC Capital Markets Global Healthcare Conference in New York, NY on Tuesday, February 23 rd at 8:00am EST.

Medicines (MDCO) Stock Price Target Lowered at Jefferies

Medicines (MDCO) Stock Price Target Lowered at Jefferies

Jefferies decreased its price target on Medicines (MDCO) stock and maintained its ‘buy’ rating.

Medicines Co. (MDCO) Stock Jumping on Q4 Results

Medicines Co. (MDCO) Stock Jumping on Q4 Results

Medicines Co. (MDCO) stock is climbing on Wednesday afternoon following the release of its 2015 fourth quarter results before today’s market open.

The Medicines Company Reports Fourth-Quarter And Full-Year 2015 Business And Financial Results

The Medicines Company Reports Fourth-Quarter And Full-Year 2015 Business And Financial Results

The Medicines Company (NASDAQ:MDCO) today announced its business and financial results for the fourth quarter and full year ended December 31, 2015.

Clive Meanwell, MD, PhD Receives Dr. Sol J. Barer Award At BioNJ Gala Event

Clive Meanwell, MD, PhD Receives Dr. Sol J. Barer Award At BioNJ Gala Event

The Medicines Company (NASDAQ:MDCO) today announced that its founder and Chief Executive Officer, Clive Meanwell, MD, PhD, has been awarded the 2016 Dr.

The Medicines Company To Announce Fourth Quarter And Full Year 2015 Financial Results On Wednesday, February 17, 2016

The Medicines Company To Announce Fourth Quarter And Full Year 2015 Financial Results On Wednesday, February 17, 2016

The Medicines Company (NASDAQ:MDCO) has scheduled its quarterly conference call for Wednesday, February 17 th at 8:30 a.

The Medicines Company Appoints Alexander J. Denner, Ph.D. To Its Board Of Directors

The Medicines Company Appoints Alexander J. Denner, Ph.D. To Its Board Of Directors

The Medicines Company (NASDAQ:MDCO) today announced that it has appointed Alexander J.

The Medicines Company To Participate In Leerink Partners 5th Annual Global Healthcare Conference

The Medicines Company To Participate In Leerink Partners 5th Annual Global Healthcare Conference

The Medicines Company (NASDAQ:MDCO) is scheduled to participate at the Leerink Partners 5 th Annual Global Healthcare Conference in New York, NY on Wednesday, February 10 th at 10:40am EST.

The Medicines Company Completes Divestiture Of Its Hemostasis Portfolio To Mallinckrodt Plc

The Medicines Company Completes Divestiture Of Its Hemostasis Portfolio To Mallinckrodt Plc

The Medicines Company (NASDAQ:MDCO) today announced that it has completed the divestiture of its hemostasis portfolio to Mallinckrodt plc.

Medicines (MDCO) Highlighted As Today's Perilous Reversal Stock

Medicines (MDCO) Highlighted As Today's Perilous Reversal Stock

Trade-Ideas LLC identified Medicines (MDCO) as a "perilous reversal" (up big yesterday but down big today) candidate

Why Medicines (MDCO) Stock is Advancing Today

Why Medicines (MDCO) Stock is Advancing Today

Medicines (MDCO) stock is climbing on Wednesday afternoon as the company explores a sale of itself.

Strong On High Volume: Medicines (MDCO)

Strong On High Volume: Medicines (MDCO)

Trade-Ideas LLC identified Medicines (MDCO) as a strong on high relative volume candidate

The Medicines Company Advances Clinical Development Of Investigational First-in-Class PCSK9 Synthesis Inhibitor For Atherosclerotic Cardiovascular Disease (ASCVD)

The Medicines Company Advances Clinical Development Of Investigational First-in-Class PCSK9 Synthesis Inhibitor For Atherosclerotic Cardiovascular Disease (ASCVD)

The Medicines Company (NASDAQ:MDCO) today announced that it has initiated study sites and begun enrolling patients in the ORION-1 Phase 2 study to compare the effect of different doses of ALN-PCSsc given as subcutaneous...

Medicines (MDCO) Stock: Weak On High Volume Today

Medicines (MDCO) Stock: Weak On High Volume Today

Trade-Ideas LLC identified Medicines (MDCO) as a weak on high relative volume candidate

The Medicines Company To Participate In J.P. Morgan 34th Annual Healthcare Conference

The Medicines Company To Participate In J.P. Morgan 34th Annual Healthcare Conference

The Medicines Company (NASDAQ:MDCO) is scheduled to present at the J.

Today's Dead Cat Bounce Stock Is Medicines (MDCO)

Today's Dead Cat Bounce Stock Is Medicines (MDCO)

Trade-Ideas LLC identified Medicines (MDCO) as a "dead cat bounce" (down big yesterday but up big today) candidate

The Medicines Company Agrees To Divest Its Hemostasis Portfolio To Mallinckrodt Plc

The Medicines Company Agrees To Divest Its Hemostasis Portfolio To Mallinckrodt Plc

The Medicines Company (NASDAQ:MDCO) today announced that it has entered into a purchase agreement pursuant to which certain subsidiaries of Mallinckrodt plc will acquire The Medicines Company's global portfolio of three...

The Medicines Company Announces Investigational Lipid Modulating Agent, MDCO-216, Phase 1 Data Published In European Heart Journal- Cardiovascular Pharmacotherapy

The Medicines Company Announces Investigational Lipid Modulating Agent, MDCO-216, Phase 1 Data Published In European Heart Journal- Cardiovascular Pharmacotherapy

The Medicines Company (NASDAQ:MDCO) today announced that the European Heart Journal - Cardiovascular Pharmacotherapy has published results of its Phase 1 study for MDCO-216, a compound under development for the reduction...

Glenn Sblendorio To Retire As President And Chief Financial Officer From The Medicines Company

Glenn Sblendorio To Retire As President And Chief Financial Officer From The Medicines Company

The Medicines Company (NASDAQ:MDCO) announced today that Glenn Sblendorio, President and Chief Financial Officer, will retire from the company effective March 31, 2016.

The Medicines Company To Participate In Oppenheimer 26th Annual Healthcare Conference

The Medicines Company To Participate In Oppenheimer 26th Annual Healthcare Conference

The Medicines Company (NASDAQ:MDCO) is scheduled to present at the Oppenheimer 26th Annual Healthcare Conference in New York, NY on Wednesday, December 9 at 8:35 am EST.

The Medicines Company Receives European Commission Approval For IONSYS® 40 Micrograms Per Dose Transdermal System (fentanyl) To Treat Post-Operative Pain In Adult Hospitalized Patients

The Medicines Company Receives European Commission Approval For IONSYS® 40 Micrograms Per Dose Transdermal System (fentanyl) To Treat Post-Operative Pain In Adult Hospitalized Patients

The Medicines Company today announced that the European Commission has granted marketing authorization for IONSYS® (40 micrograms per dose transdermal system), with active ingredient fentanyl, for the management of...

Federal Circuit Overturns District Court Decision On Angiomax Patents; Grants The Medicines Company's Request For Rehearing Of Appeal

Federal Circuit Overturns District Court Decision On Angiomax Patents; Grants The Medicines Company's Request For Rehearing Of Appeal

The Medicines Company's petition for en banc review of the U.S.

Medicines Company (MDCO) Marked As A Barbarian At The Gate

Medicines Company (MDCO) Marked As A Barbarian At The Gate

Trade-Ideas LLC identified Medicines Company (MDCO) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

Alnylam Pharmaceuticals And The Medicines Company Announce That New ALN-PCSsc Results From Late-Breaking Presentation At American Heart Association Meeting Confirm Potential For Bi-Annual Hypercholesterolemia Dose Regimen

Alnylam Pharmaceuticals And The Medicines Company Announce That New ALN-PCSsc Results From Late-Breaking Presentation At American Heart Association Meeting Confirm Potential For Bi-Annual Hypercholesterolemia Dose Regimen

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, and  The Medicines Company (Nasdaq:MDCO), a leading biopharmaceutical development and cardiovascular product company, today...

The Medicines Company To Present New Data On Cardiovascular Portfolio At American Heart Association (AHA) Scientific Sessions

The Medicines Company To Present New Data On Cardiovascular Portfolio At American Heart Association (AHA) Scientific Sessions

The Medicines Company today announced it will present new data from both its established antithrombotic portfolio and investigational hypercholesterolemia pipeline at the 2015 Scientific Sessions of the American Heart...

Medicines Company (MDCO) Flagged As Strong On High Volume

Medicines Company (MDCO) Flagged As Strong On High Volume

Trade-Ideas LLC identified Medicines Company (MDCO) as a strong on high relative volume candidate

The Medicines Company Reports Third-Quarter And First Nine Months 2015 Business And Financial Results

The Medicines Company Reports Third-Quarter And First Nine Months 2015 Business And Financial Results

The Medicines Company (NASDAQ:MDCO) today announced its business and financial results for the third quarter and the nine months ended September 30, 2015.

Results Of First-in-Man Study With Investigational Anesthetic ABP-700 Presented At ANESTHESIOLOGY® 2015 And International Society Of Anesthetic Pharmacology Annual Meetings

Results Of First-in-Man Study With Investigational Anesthetic ABP-700 Presented At ANESTHESIOLOGY® 2015 And International Society Of Anesthetic Pharmacology Annual Meetings

Results of the first-in-man study, ANVN-01, with ABP-700, a positive allosteric GABA A receptor modulator in development for general anesthesia and procedural sedation, were presented at the annual meetings of...